Media headlines about Cambrex (NYSE:CBM) have been trending positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cambrex earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.7812658511002 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Cambrex (CBM) opened at $51.65 on Friday. The firm has a market capitalization of $1,692.98, a price-to-earnings ratio of 17.22, a price-to-earnings-growth ratio of 1.25 and a beta of 2.27. Cambrex has a 12-month low of $42.55 and a 12-month high of $62.95.

Cambrex (NYSE:CBM) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.08. The firm had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.47 EPS. equities analysts expect that Cambrex will post 2.97 earnings per share for the current year.

Separately, Craig Hallum reiterated a “buy” rating and set a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $62.33.

ILLEGAL ACTIVITY WARNING: “Cambrex (CBM) Given News Sentiment Score of 0.28” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with Analyst Ratings Network's FREE daily email newsletter.